Navidea Biopharmaceuticals, Inc. Receives $7.5M Cash From Cardinal Health In Lieu Of Contingent Milestone Payment; Shares Resumed Trading
Continuing the Company's Fix, Fund, Propel approach, the cash payment from Cardinal Health aligns strategic goals while solidifying immediate capital for funding Phase IIb and Phase III trials.Navidea Biopharmaceuticals,